THE GBM AGILE VISION
Ultimately, GBM AGILE will evaluate multiple therapies simultaneously for patients with newly diagnosed and recurrent GBM – the deadliest brain cancer.
Designed as a learning system to more efficiently and rapidly identify effective therapies, GBM AGILE’s nimble model enables multiple drugs (and combinations of drugs) to be screened simultaneously and over time.
The intent is to lower the cost, time and number of patients required to evaluate potentially new effective therapies for GBM patients faster and more efficiently than ever before.
THE GBM AGILE CLINICAL TRIAL
While GBM AGILE (clinicaltrial.gov identifier: NCT03970447) plans to test multiple drugs from different companies over time, the first drug entering the trial will be Bayer’s drug regorafenib. The regorafenib arm of GBM AGILE is now open for enrollment at the trial’s first clinical site, the Henry Ford Cancer Institute. Learn more here.
By the end of 2019, GBM AGILE will open in over 40 academic medical centers and community-based institutions across the United States, with plans to expand across Europe, China, Canada, and Australia through 2020.
GBM AGILE is sponsored by the Global Coalition for Adaptive Research (GCAR) a nonprofit organization comprised of some of the world’s foremost clinical, translational, and basic science investigators.
NATIONAL BRAIN TUMOR SOCIETY’S SUPPORT OF GBM AGILE
National Brain Tumor Society, along with the National Foundation for Cancer Research (NFCR) and the Asian Fund for Cancer Research, is a key strategic partner for GCAR and the GBM AGILE platform, providing philanthropic and advocacy support.
Alongside our partners, we believe deeply in the potential of this nimble, transformative new approach to clinical trials and are proud to have invested in GBM AGILE.
For questions regarding philanthropic support for GBM AGILE, please contact the NBTS Development Office at email@example.com or 617-237-1731.